Creo Medical Group PLC Speedboat in BSG Endoscopy best video abstract
12 March 2019 - 8:19PM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
12 March 2019
Creo Medical Group plc
("Creo" or the "Company")
Speedboat features in BSG Endoscopy Live 2019 best video
abstract
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
the Company's Speedboat device was the key subject of the winner of
"The Best Video Abstract" during last week's BSG Endoscopy Live
2019 conference in Gateshead. The presentation, "Endoscopic
submucosal dissection with the 'Speedboat RS2 device'; a
multi-modality device", was delivered to this gathering of
prestigious faculty of UK and international endoscopists, and
conference delegates.
The abstract was written by UK experts in the field of
Gastrointestinal ("GI") therapeutic endoscopy and users of Creo's
Speedboat device for colorectal endoscopic submucosal dissection,
an advanced surgical procedure using endoscopy to remove
gastrointestinal pre-cancerous lesions that have not entered the
muscle layer. The authors were:
- Professor Brian Saunders, Consultant Gastroenterologist at St. Mark's Hospital Foundation
- Dr Zacharias Tsiamoulos, Consultant Gastroenterologist at
Queen Elizabeth the Queen Mother Hospital, East Kent
- Dr Ioannis Stasinos, Endoscopy Research Fellow at St. Mark's Hospital Foundation, London
Endoscopy Live 2019 was the 3rd national live endoscopy meeting
organised by the BSG and was held at the Sage Gateshead on 7 and 8
March, showcasing advances in UK Endoscopy and bringing together
consultant gastroenterologists from across the UK, trainees
interested in gastroenterology, surgical colleagues and nurses.
Craig Gulliford, Chief Executive Officer of Creo, commented:
"For the authors to win the best video abstract at such a key
scientific meeting is another important step in the recognition and
momentum that is being generated by the clinical use of the
Speedboat Device. It was clear throughout the presentation of the
video abstract that the Speedboat technology provided precise
dissection and controlled haemostasis with a single device, which
shows the potential of the technology to simplify these procedures
for the clinical team and most importantly generate effective
patient outcomes. This was all the more fitting as a key theme of
the meeting was how using technology can make difficult therapeutic
endoscopy simpler."
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Helen Cresswell Mob: +44 (0)7841 917 679
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing a safer, less-invasive and more
cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRALIFLAVRIFLIA
(END) Dow Jones Newswires
March 12, 2019 05:19 ET (09:19 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024